EMV CAPITAL PLC

Post-Annual General Meeting Information • Jun 30, 2025

National Storage Mechanism | Additional information

RNS Number : 0094P

EMV Capital PLC

30 June 2025

For immediate release

EMV Capital plc

("EMVC" or the "Company")

Result of Annual General Meeting

EMV Capital Plc (AIM: EMVC), the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2025 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today.

Result of Annual General Meeting

Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution. The proxy voting results are as follows:

Resolution	For	%	Against	%	Vote Total	Vote Total as % of Issued Share Capital	Withheld*
1.    To receive and adopt the Company's Annual Report and Accounts for the period ended 31 December 2024	8,703,874	100.0%	1,617	0.0%	8,705,491	31.4%	266
2.    To receive and approve the Directors' Remuneration Report	8,585,144	98.8%	106,993	1.2%	8,692,137	31.3%	13,620
3.    To reappoint BDO LLP as the auditors for the forthcoming year	8,696,626	99.9%	8,865	0.1%	8,705,491	31.4%	266
4.    To authorise the Audit Committee in determining the Auditors' remuneration	8,694,933	100.0%	2,558	0.0%	8,697,491	31.3%	8,266
5.    To confirm the reappointment of Dr Charles Spicer as a director	8,689,567	99.9%	6,617	0.1%	8,696,184	31.3%	9,573
6.    To confirm the reappointment of Dr Ilian Iliev as a director	8,689,567	99.9%	6,617	0.1%	8,696,184	31.3%	9,573
7.    To confirm the reappointment of Edward Hooper as a director	8,689,567	99.9%	6,617	0.1%	8,696,184	31.3%	9,573
8.    To confirm the reappointment of Dr Jonathan Robinson as a director	8,689,567	99.9%	6,617	0.1%	8,696,184	31.3%	9,573
9.    To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006	8,178,221	95.2%	414,852	4.8%	8,593,073	30.9%	112,684
10.  To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of up to 5,553,460 shares	8,233,170	94.7%	456,228	5.3%	8,689,398	31.3%	16,359

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

For more information, please contact:

EMV Capital plc	via Rosewood
Ilian Iliev, CEO
Panmure Liberum Limited  (NOMAD and Broker)	+44 (0)20 7886 2500
Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
Rosewood  (Financial PR)	+44 (0)20 7653 8702
John West / Llewellyn Angus / Lily Pearce

About EMV Capital plc (EMVC)

EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGWPUGPQUPAGGU